Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPd in Relapsed/Refractory AL Amyloidosis Previously Exposed to Daratumumab
NCT04270175Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2021
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in light-chain amyloidosis, sponsored by Weill Cornell Medicine. Started Apr 2021; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT04270175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270175.